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Background: The prevalence of MRSA in patients with CF has risen in recent years. We adhere to a policy of segregation and barrier nursing to
manage patients with MRSA, and we actively pursue eradication of MRSA. We have evaluated our experiences of MRSA infection in our large
adult CF centre.
Method: A retrospective review of all MRSA-positive patients from 1998 to 2008 was undertaken. Isolates were subjected to molecular
identification to elucidate possible patient-to-patient transmission events. Eradication attempts were scrutinised.
Results: We have maintained a low incidence and prevalence (below 3%) of MRSA within this large cohort. A total of 15 pulsotypes of MRSA
were identified among the 24 isolates examined, epidemiological data suggested no patient–patient transmission. Based on 6 month follow-up
data, successful eradication was achieved in 81% patients. This includes those who had harboured infection for some time. Twenty-one (80.8%)
required only one course of treatment, 3 (11.6%) patients required two different regimes and 2 (7.5%) required three courses to fully eradicate the
organism.
Conclusion: Strict infection control procedures can control MRSA infection and keep the prevalence low in CF clinics. Eradication is achievable
in the majority of patients even when significant time has lapsed from initial isolation. In some instances, up to 3 courses of antibiotics were
required to achieve eradication.
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Methicillin-resistant Staphylococcus aureus (MRSA)
remains high on the political healthcare agenda as the
incidence/prevalence in the general population continues to
rise [1]. Within the United Kingdom (UK) epidemic MRSA☆ The authors can confirm that this was an unfunded study.
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doi:10.1016/j.jcf.2009.11.009(EMRSA)-15 and -16 are the predominant healthcare associated
MRSA (HA-MRSA) strains encountered [2].
MRSA infection in patients with CF is also becoming an
increasingly difficult management challenge. The prevalence
amongst this group of patients in the United States continues to
rise with Cystic Fibrosis Foundation Registry data reporting a
prevalence of 21.2% in 2007 [4–6].
There are national recommendations for the control and
management of MRSA infection within the UK [1] and also
specific recommendations pertaining to CF [7].
Segregation of patients with CF who are colonised with
MRSA is recommended [7], a policy we adhere to at our centre.
Previous work has demonstrated the potential for patient-d by Elsevier B.V. All rights reserved.
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CF [8].
Despite the increasing incidence being a significant concern,
controversy abounds about the effect of MRSA on CF lung
disease. Several conflicting reports have suggested either
neutral [3,10,11] or deleterious effects of MRSA infection on
CF lungs [4,9] but the most recent publication based on North
American CF Foundation registry data suggests a hastened
decline in FEV1 in affected individuals [12].
There is no strong consensus regarding the management of
MRSA infection. Many centres will opt for attempted eradication
and several potential antibiotic regimes have been reported to try
and achieve this [13–19]. TheUKCFTrust has published a report
which advocates eradication treatment [7].
The Manchester Adult Cystic Fibrosis Centre, a large
regional unit, has a strict isolation policy for MRSA-positive
patients based on strong infection control principles. We have a
large dedicated CF building with single accommodation for all
in-patients. Patients with Burkholderia cepacia complex
infection are housed on a separate respiratory ward. We have
a dedicated out-patient clinic area attended in cohorts defined by
their sputum microbiology. In-patients with MRSA are isolated
in rooms with en-suite facilities and barrier nursed throughout
their stay. These patients attend clinic outside of normal clinic
times and are segregated and barrier nursed for the duration of
their visit. We have assiduously pursued a protocol for the
attempted eradication of MRSA from CF lungs since 2005.
In this study we reviewed our experience of MRSA infection
with particular aims of assessing the efficacy of our infection
control policy and eradication strategies.
2. Method
We conducted a retrospective review of our experience of
patients infected with MRSA. Cases were identified from our
microbiology and CF unit databases.
A structured proforma was designed to extract information
from case records looking at patient demographics, lung function,
eradication regimes used and relevant epidemiological factors
including occupation, in-patient days and risk factors for MRSA
acquisition.
A proportion of the MRSA isolates were referred to the
national Staphylococcus reference laboratory for detailed char-
acterisation, including pulsed-field gel electrophoresis (PFGE), to
help evaluate possible patient-to-patient transmission events.Table 1
Incidence and prevalence of MRSA infection within patients attending MACFC 199
Year 1998 1999 2000 2001 200
Patients attending unit 205 215 220 228 241
New cases MRSA 4 0 3 3 1
Incidence rate (%) 1.95 0 1.36 1.31 0
Number of patients with MRSA 4 0 3 3 2
Prevalence rate (%) 1.95 0 1.36 1.31 0
Key: Patient numbers attending MACFC since 1998 and number of new isolates ofMRSAs were subjected to Pulsed-Field Gel Electrophoresis
(PFGE) following macro-restriction of chromosomal DNA with
SmaI, as described previously [20].
Eradication of MRSA infection was defined as the presence of
3 consecutive negative MRSA screens (sputum and peripheral
surface screening swabs) over a 6 month period following initial
treatment in the absence of additional MRSA effective antibiotics
or decolonization procedures.
3. Results
3.1. Patient demographics
MRSA from either sputum or from peripheral swabs was
recovered from 37 of 469 (8.1%) patients who attended the
Manchester Adult CF Centre since 1998. Of these, 34 (91.2%)
yielded a positive sputum sample (8 also had positive swab
results.); 3 patients had positive peripheral swabs only. Two
patients hadMRSA-positive skin swabs and 1 patient hadMRSA-
positive swabs from their nose.
The mean (se) age of the patients at the time of MRSA
acquisition was 25.6 (1.2) years. Mean forced expiratory
volume in 1 s (fev1) was 2.2 (0.2) litres. Mean FEV1 percent
predicted was 58.1 (3.8)%. Mean body mass index of the group
was 20.8 (0.6) kg/m2. Other pathogens isolated from the
sputum included 19 (51.4%) sporadic pseudomonas strains, 9
(24.3%) transmissable pseudomonas strains [21,22], 5 (13.5%)
burkholderia cepacia complex infections and 4 (10.8%) other
organisms.
3.2. Epidemiology
The incidence and prevalence data of positive cultures for
MRSA is displayed in Table 1. Both the incidence and
prevalence have remained relatively low throughout this period
with neither rising above 3%.
A total of 14 (37.8%) patients tested positive for MRSA prior
to attending MACFC. Of these, 11 (78.5%) acquired MRSA
whilst attending their paediatric centre and 3 (12.5%) were
transferred from other adult CF centres with previous positive
MRSA samples. None of these patients had had a previous
attempt at eradication prior to attending our centre.
An additional 14 (37.8%) patients were shown to have a
clear risk factor for acquiring MRSA infection either as a result
of their occupation, lifestyle or sputum microbiology (e.g. those8–2009.
2 2003 2004 2005 2006 2007 2008 2009
249 250 257 287 310 333 334
2 3 5 1 7 5 3
.4 0.8 0.4 1.94 0.34 2.25 1.5 0.89
3 4 7 3 9 9 9
.82 1.2 0.4 2.72 1.05 2.9 2.7 2.69
MRSA per year. Incidence and prevalence are displayed as rate per population.
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These are displayed in Table 2.
3.3. Strain typing data
Strain typing results were available on 24 (64.8%) isolates.
The results of our pulsed-field gel electrophoresis analysis are
represented in Fig. 1. Twelve of the identified pulsotypes were
sub-types of EMRSA-15. Four proved indistinguishable and
were identified as EMRSA-15 variant B3. Five were sub-types
of EMRSA-16 (2 of which were indistinguishable and identified
as EMRSA-16 variant A1). The remainder (n=7) were
representative of more minor lineages of HA-MRSA circulating
in the UK.
Case records of patients from whom identical strains of
MRSA were isolated were examined. These patients were not in
direct contact with one another. They did not share clinic times
or overlap on in-patient admissions. The patients were not
acquainted socially. We suggest that this information shows that
the likelihood of cross-infection between patients was extreme-
ly unlikely. Healthcare workers are not routinely screened for
MRSA at this institution but a policy detailing practice as regard
barrier nursing is adhered to.
3.4. Eradication
MRSA eradication was attempted in all 37 patients. Of these,
5 patients have completed their initial treatment but remain
within the 6 month observation period post treatment.
Six (16%) patients failed to eradicate MRSA despite
treatment. Twenty-six (70% total; 81% patients completed
eradication) have undergone successful eradication treatment.
Of these, 21 (80.8%) required only one course of treatment to
fully eradicate MRSA; 3 (11.6%) patients required two different
regimes and 2 (7.5%) required three courses of treatment to
fully eradicate the organism.
The 3 patients who were MRSA-positive on peripheral skin
or nasal swabs only were successfully eradicated with topical
decolonization methods only. Of the 8 patients who were
MRSA-positive in sputum and peripheral swabs 6 have beenTable 2
Risk factors for acquisition of MRSA amongst the patient cohort.
Risk factor Number of patients
Bcc infection 3
Healthcare professional 3
Admission to non-CF hospital wards 4
Family members with MRSA 3
Married to healthcare professional 1
Key: 14 of 37 (37.8%) of patients from whom MRSA was isolated had a risk
factor contributing to acquisition. The 14 (37.8%) patients who had isolated
MRSA prior to attending MACFC were excluded from this analysis.
Bcc=Burkholderia cepacia complex. Patients who required in-patient admis-
sion were nursed on general respiratory wards for reasons of segregation.
Admission to non-CF hospital wards. Patients had been admitted to other wards
either within our trust or other surrounding hospitals and MRSA was isolated
from sputum samples at flowing out-patient attendance.successfully eradicated with combination treatment. Of the 2
who remain MRSA-positive despite eradication MRSA is
consistently isolated from the sputum.
MRSA was recovered from 4 (15.3%) patients following a
successful eradication and 6 month follow-up period. Of
these, one course of repeat eradication has been successful in
3 (75%). Two of these patients had a risk factor for the
recurrence of MRSA infection. One patient had Bcc infection
and was nursed on a general respiratory ward as an in-patient
and one patient had a family member with MRSA. Unfortu-
nately strain typing was unavailable in 1 of these patients. In the
patient whose family member had MRSA infection an identical
pulsotype of MRSA was identified on each occasion suggesting
re-infection. One of the 2 patients with no clear risk for re-
isolation had separate pulsotypes of MRSA identified at initial
acquisition and subsequent re-culture, suggesting a re-infection
rather than relapse. The other patient re-isolated an identical
strain of MRSA (EMRSA-15 variant B3) suggesting relapse.
Of the 14 patients who had MRSA at transfer into our centre,
MRSA was successfully eradicated in 9 (64.3%). Four (28.6%)
patients have not eradicated MRSA and 1 (7.1%) remains on the
eradication protocol.
Many different eradication regimes were used. The choice of
regime was largely based on the susceptibility pattern of the
infecting MRSA, although a formal protocol which included
nebulised Vancomycin was introduced in 2005. We use 2 oral
antibiotics for a minimum of 6 weeks. First line choices include
Fusidic acid 500 mg tds, Rifampicin 300 mg bd and Trimeth-
oprim 200 mg bd. Choice of antibiotics is dependent on
sensitivity pattern and patient tolerances. The regimes
are detailed in Table 3. Topical decolonization measures are
used to treat oral, skin and nasal carriage. Agents used
include: vancomycin 2% in orobase paste for 5 days; mupirocin
2% w/w ointment for 5 days for nasal carriage; and triclosan 2%
w/w solution for skin carriage.
Minor adverse reactions were occasionally experienced
during eradication and dictated a change in treatment. All
resolved after the regime was altered. Reactions to oral
antibiotics included nausea and vomiting, diarrhoea and
thrombocytopenia. Nebulised Vancomycin was always admin-
istered as an in-patient at a dose of 200 mg four times a day for a
total of 5 days alongside bronchodilators. Despite this, its use
was associated with chest tightness in a small number of
patients. Three (16.6%) patients were unable to complete the
full treatment course.
4. Discussion
This review of our large adult CF centre's experience with
MRSA infection has produced interesting results.
The incidence/prevalence of MRSA infection within our
cohort of patients was significantly below those figures that
have been previously published. Recent CF registry data
suggest 21.2% patients in 2007 [5]. In 2008 The CF
Trust published a report with specific recommendations
for the management of MRSA in CF centres including
addressing segregation, hygiene and surveillance [7]. Similar
Fig. 1. Results of PFGE analysis on MRSA isolates in MACFC patients. Key: Visual representation of PFGE performed on 24 MRSA isolates from patients with CF
attending MACFC. Results confirmed all strains were HA-MRSA. EMRSA-15 was isolated in 12 patients and EMRSA-16 in 5 patients. Other isolates were more
minor lineages of HA-MRSA.
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published survey of centres discovered that only 65% of centres
had a formal written infection control policy whilst only 58% of
them had a policy specific to MRSA [24]. We believe our dataTable 3
Antibiotic regimes used for MRSA eradication and success rates.
Antibiotic regime No. times
used
No. times
successful
Ongoing
follow-up
Nebulised Vancomycin plus 2
oral antibiotics
18 11 3
Rifampicin and fucidin 13 9 1
Rifampicin and trimethoprim 1 1
Linezolid and trimethoprim 1 1
Doxycycline and trimethoprim 1 0 1
Septrin and fucidin 1 0 1
Fucidin and trimethoprim 1 0
Oral Antibiotic 17 10 1
Rifampicin and fucidin 4 4
Linezolid 6 5
Doxycycline 1 1
Fucidin and trimethoprim 1 0 1
Rifampicin and trimethoprim 2 0
Linezolid and fucidin 1 0
Rifampicin and doxycycline 1 0
Fucidin and oxytetracycline 1 0
Intravenous antibiotics 3 2
Vancomycin 1 1
Vancomycin and teicoplanin 1 1
Vancomycin and cefuroxime 1 0
Key: An overview of all antibiotic regimes used to eradicate sputum-positive
MRSA in patients with CF attendingMACFC. Antibiotic choice was dictated by
sensitivity patterns and patient tolerances. From 2005 all patients have been
considered for nebulised Vancomycin. Patients who have received a course of
treatment who have negative cultures following this but remain within a 6 month
observation period are listed in the column titled ‘Ongoing follow-up’.support the need for all centres to operate a policy of
segregation and infection control.
Patient-to-patient transmission of microbes including MRSA
remains an active concern. A report by Givney et al. [8] detailed
how in a unit without a formal infection control policy
molecular analysis of microbial isolates could demonstrate
likely cross-infection between patients.
We have used strain typing and PFGE to further evaluate
our infection control practice. We have shown that the
majority of MRSA in this study represented distinct strains.
In those isolates that were genetically indistinguishable, we
reviewed the records of the patients involved. Patients did not
share overlapping clinic appointments or in-patient admis-
sions. They were not in social contact with one another.
Further, the strains involved (EMRSA-15 variant B3 and
EMRSA-16 variant A1) are among the commonest sub-types
of UK EMRSA. We therefore feel that patient-to-patient
transmission was extremely unlikely as no contact between
patients could be demonstrated. Staff were not routinely
screened for MRSA but were expected to follow guidelines on
barrier nursing and isolation.
The utility of strain typing analysis for this purpose has been
reported previously. Molecular analysis has been demonstrated
to suggest cross-infection of MRSA as identical clones have
been isolated from different patients [25]. Another study
confirms our findings as 6 different pulsotypes of MRSA
were identified from 7 patients suggesting a low level of
transmission between patients [26].
HA-MRSA strains are more predominant within the CF
population [27]. The result of our strain typing confirms this
with all isolates recognised as HA-MRSA.
We were able to demonstrate in a number of potential risk
factors for MRSA acquisition. These included transfer from
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followed), being nursed on general respiratory or medicine
wards and working as or living with a healthcare professional.
Health care professionals with CF are certainly at risk of
MRSA infection as demonstrated previously by Downey et al.
One patient who was health care professional was treated for 1
pulsotype of MRSA and acquired a further pulsotype
following a 6 month period of negative isolates [28]. However
CA-MRSA rates are increasing in CF centres in other countries
[29].
We have described our experience of eradicating MRSA
infection. We have been able to report a very high eradication
success rate of 81% which compares favourably to the
published experiences [13–19]. We used a varying regime of
antibiotics tailored to each individual based primarily on
sensitivity patterns and patient tolerances. Based on previously
published data [14,15] we have incorporated nebulised
vancomycin into this regime when tolerated since 2005.
We describe success in eradicating MRSA that has been
present in sputum for some time including in those patients
who acquired MRSA in paediatric care and had not
undergone any previous eradication attempts. Many of
these patients had harboured MRSA for many years prior to
transfer to our unit and were still able to achieve successful
eradication.
Although one course of treatment was successful in
eradicating MRSA in 21 (80.8%), some patients required two
(3, 11.6%) or three (2, 7.5%) courses of treatment before
successful eradication could be achieved. Based on our results
we would recommend that eradication should utilise a
combination of treatments including where appropriate topical
measures, as described earlier, two oral antibiotics and
nebulised antibiotics. Our first line treatments include rifampi-
cin 300 mg bd and fucidin 500 mg tds for 6 weeks in
combination with vancomycin 200 mg qds for 5 days. We
would recommend that at least three attempts at eradication
should be made before MRSA infection is deemed to be
chronic.
There are some limitations to our study including its
retrospective design. Strain typing has not been done on all
isolates at this point. Staff have not had MRSA screening as part
of routine practice.
In conclusion, these data confirm the importance of
possessing and adhering to a strict infection control policy
which incorporates measures aimed at suppressing MRSA
infection. This will help keep the incidence/prevalence of
MRSA infection low and minimise the opportunity for
cross-infection within a centre. Some patients will remain
at risk of acquiring MRSA infection by virtue of their
other microbiological status or profession and they should
be made aware of the risk and strategies to help minimise
this.
For those patients who do acquire MRSA, aggressive
attempts at eradication should be made even if there has been
a considerable time lapse since the initial infection. A high
success rate can be achieved with individualised and tailored
antibiotic treatment. We advocate three separate attempts ateradication before conceding that patients have long-term
colonisation with MRSA.
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